Remission Assessment by Circulating Tumor DNA in Large B-Cell Lymphoma

202513 citationsJournal Articlehybrid Open Access

Authors

Mark Roschewski · National Cancer Institute

David M. Kurtz · Foresight Science & Technology (United States)

Jason R. Westin · The University of Texas MD Anderson Cancer Center

Ryan C. Lynch · Fred Hutch Cancer Center

Ajay K. Gopal · Fred Hutch Cancer Center

Stefan Alig · Essen University Hospital

Brian J. Sworder

Abstract

Ultrasensitive ctDNA detection after frontline LBCL therapy is more prognostic than conventional radiographic response criteria. A refined definition of remission with ctDNA-MRD may improve clinical and psychological outcomes for patients with LBCL.

Topics & Keywords

Lymphoma Diagnosis and Treatment Cancer Genomics and Diagnostics Lung Cancer Treatments and Mutations

Publication Details

Published in: Journal of Clinical Oncology

Volume 43, Issue 34, pp. 3652-3661

DOI: 10.1200/jco-25-01534

Field-Weighted Citation Impact: 18.72

Command Palette

Remission Assessment by Circulating Tumor DNA in Large B-Cell Lymphoma

Authors

Abstract

Topics & Keywords

Publication Details